Treatment for Transient Ischemic Attack
Immediately start antiplatelet therapy after brain imaging to prevent stroke, with the specific regimen determined by whether the TIA is cardioembolic or noncardioembolic.
Noncardioembolic TIA
Immediate Antiplatelet Therapy (Category 1 Evidence)
Daily long-term antiplatelet therapy should be prescribed immediately for secondary prevention of stroke and other vascular events 1. The urgency cannot be overstated—TIA is a medical emergency with peak stroke risk within 48 hours 2.
First-Line Options (Choose One):
- Aspirin 50mg + sustained-release dipyridamole 200mg twice daily (Category 1) 1
- Clopidogrel 75mg daily (Category 1, may be slightly more effective than aspirin alone) 1
- Aspirin 75-162mg daily (Category 1) 1, 3
The choice depends on cost, tolerance, and coexisting vascular conditions 3.
High-Risk Noncardioembolic TIA: Short-Term Dual Antiplatelet Therapy
For high-risk TIA (ABCD2 score ≥4, weakness or speech disturbance >5 minutes, recurrent events, or significant ipsilateral large artery disease), use aspirin 75-162mg + clopidogrel 75mg daily for the first month only 3, 4, 5. This reduces stroke risk from 7.8% to 5.2% (hazard ratio 0.66) 5. Beyond one month, dual therapy increases bleeding risk without additional benefit 3, 6.
If Already on Aspirin When TIA Occurs:
Switch to either:
- Clopidogrel 75mg daily, OR
- Aspirin 25mg + sustained-release dipyridamole 200mg twice daily (Category 3) 1
Critical Caveat: Avoid Oral Anticoagulation
Do not use oral anticoagulation for noncardioembolic TIA—no documented benefit over antiplatelet therapy at INR 2.0-3.0, but higher risk of cerebral hemorrhage at INR >3.0 (Category 1) 1.
Cardioembolic TIA
Atrial Fibrillation (Valvular or Nonvalvular)
Long-term oral anticoagulation is mandatory (Category 1) 1, 7:
- Target INR 2.5 (range 2.0-3.0) with warfarin, OR
- Preferred: Direct oral anticoagulants (apixaban, dabigatran, edoxaban, or rivaroxaban) over warfarin for nonvalvular AF (Class I, Level B-R) 7
Timing of anticoagulation initiation:
- TIA patients: Start immediately (Class IIa, Level C-EO) 7
- Stroke patients at high hemorrhagic risk: Delay beyond 14 days (Class IIa, Level B-NR) 7
- Stroke patients at low hemorrhagic risk: Start 2-14 days after event (Class IIb, Level B-NR) 7
If oral anticoagulation is contraindicated:
- Use aspirin 325mg daily, or clopidogrel 75mg if aspirin intolerant (Category 1) 1
Other Cardioembolic Sources
Anticoagulation is NOT recommended for TIA patients in sinus rhythm (Category 1) 1 UNLESS high-risk cardiac sources exist:
- Paroxysmal atrial fibrillation/flutter
- Recent myocardial infarction
- Mechanical heart valve prosthesis
- Mitral stenosis
- Intracardiac clot
- Severe dilated cardiomyopathy (ejection fraction ≤20%) (Category 4) 1
For patent foramen ovale, mitral valve prolapse, or strands: Use antiplatelet therapy (Category 3) 1
For prosthetic heart valves already on adequate anticoagulation: Add aspirin 81mg daily or dipyridamole (Category 3) 1
Special Situations
Concurrent Acute Coronary Syndrome
TIA with unstable angina or non-Q-wave MI: Use clopidogrel 75mg + aspirin 75-100mg (Category 1) 1
Pre-Carotid Endarterectomy
Start aspirin 50-325mg before surgery unless contraindicated (Category 2) 1
Drug Interactions Warning
Avoid concurrent use of warfarin with: feverfew, garlic, ginkgo biloba, ginger, ginseng (alter bleeding time). St. John's Wort reduces digoxin levels and enhances warfarin metabolism (Category 4) 1.
Critical Pitfalls to Avoid
- Do NOT use ABCD2 score alone to triage or delay treatment—patients with scores ≤3 may still be at significant stroke risk 4
- Do NOT continue dual antiplatelet therapy beyond 3-4 weeks in noncardioembolic TIA without specific indication (increased bleeding risk) 3, 6
- Do NOT use clopidogrel if considering thrombolysis—ensure brain imaging first 8
- Do NOT use ticlopidine—clopidogrel has fewer side effects and requires less monitoring (Category 4) 1
Essential Concurrent Management
Beyond antiplatelet/anticoagulation therapy: